Loading data for HCWB — first visit, this takes a few seconds.
HCW Biologics Inc. (HCWB)
NasdaqCM: HCWB
· 即時價格 · USD
2.24
-0.19 (-7.82%)
收盤價： Sep 11, 2026, 3:59 PM
2.20
-1.79%
盤後: 6:59 PM
股價、關鍵數字和最新消息，都在這一頁。
HCW Biologics Inc.（HCWB）股價、分析與資料
-7.82% (1D)
| 買價 | 1.73 |
| 市值 | 4.11M |
| 營收 (ttm) | 6.72M |
| 淨利（ttm） | -21.4M |
| 2.38 | |
| -16.62 | |
| n/a | |
| -4.07 | |
| P/B (ttm) | 0.49 |
| P/S (ttm) | 0.61 |
| 財報日期 | n/a |
| 賣價 | 2.85 |
| 成交量 | 93,586 |
| 20 日平均成交量 | 182,750 |
| 開盤價 | 2.43 |
| 前收盤價 | 2.43 |
| 當日區間 | 2.20 - 2.44 |
| 52 週範圍 | 1.50 - 36.65 |
| 分析師 | n/a |
| 目標價 | n/a |
| 股利 | n/a |
| 除息日 | n/a |
關於 HCWB
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which ...
完整的公司簡介財報驚奇
HCW Biologics 已於 Aug 14, 2026 公布季度財報：
- 營收為 $135.57K 低於預期 $0, 年增 1969.74% 成長.
- 每股盈餘為 -11.58 低於預期 -9.60, 年增 71.58% 成長.
